TXG · 10x Genomics, Inc.
Is TXG setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on 10x Genomics, Inc., in one place.
Today's breakout radarIs TXG setting up for a breakout?
Breakout Radar API →TXG reports earnings on Nov 5, 2026 — a breakout right before a report can reverse on the numbers.
Not today. TXG is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about TXG?
Stock Sentiment API →Bulls: 10X Genomics (TXG) has been rising since around $20 in May, reaching a high of $102.8 in October — nearly a 500% gain — and is ARK's top-ten holding. The stock resolved higher after consolidating around its 50-day moving average, held up best during the indices' downturn, and fired upward +9.2 on a weekly TTM Squeeze scan. It printed a clean breakout from multi-day tightness (+8% in pre-market), with the daily 8 and 21 EMAs, weekly 8 EMA and 50 SMA converging at one confluence point as volume dried up, and one trader went long at $76.38. Genomics is among the strongest sectors, with $ARKG breaking the AVWAP of this year's high and TXG named alongside $ILMN as the two best names.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about TXG?
News Sentiment API →No recent news reading for TXG. The News Sentiment API reads today's headlines on any US stock.
Are TXG insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · SULIMAN SHEHNAAZ$101K · Sep 22, 2026
- Sold · SULIMAN SHEHNAAZ$185K · Sep 22, 2026
- Sold · SULIMAN SHEHNAAZ$107K · Sep 22, 2026
- Sold · SULIMAN SHEHNAAZ$49K · Sep 22, 2026
- Sold · SULIMAN SHEHNAAZ$23K · Sep 22, 2026
How is 10x Genomics, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $151.0M | -13% | −$17.9M | $-0.14 |
| Mar 31, 2026 | $150.8M | -3% | −$13.5M | $-0.10 |
| Sep 30, 2025 | $149.0M | -2% | −$27.5M | $-0.22 |
| Jun 30, 2025 | $172.9M | +13% | $34.5M | $0.28 |
From the company's SEC filings (10-Q and 10-K).
What does 10x Genomics, Inc. expect?
Company Guidance API →- full year 2026 · revenue · 8-K filed Aug 6, 2026
“10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $610 million to $630 million, versus the previous range of $600 million to $625 million.”
- full year 2026 · revenue · 8-K filed May 7, 2026
“10x Genomics is maintaining its full year 2026 revenue guidance of $600 million to $625 million.”
- full year 2026 · revenue · 8-K filed Feb 12, 2026
“10x Genomics expects full year 2026 revenue to be in the range of $600 million to $625 million.”
- Fourth Quarter 2025 · revenue · 8-K filed Nov 6, 2025
“10x Genomics expects fourth quarter 2025 revenue to be in the range of $154 million to $158 million, representing a 6% decline from the corresponding prior year period and 5% growth sequentially at the midpoint.”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.